Cytokinetics jumps as Needham reiterates omecamtiv bull thesis Cytokinetics ( CYTK +7.6% ) rallies after Needham's Chad Messer reminds investors that despite a misread by the media, last month's ATOMIC-AHF readout was actually in line with expectations . "Significant increases in systolic injection and reduction in worsening of heart failure while actually lowering heart rate, distinguish omecamtiv from older inotropic agents [and] are more than positive ...
Oct. 11, 2013 - Seeking Alpha